These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18236781)

  • 1. Physicochemical compatibility of nebulizable drug mixtures containing dornase alfa and ipratropium and/or albuterol.
    Krämer I; Schwabe A; Lichtinghagen R; Kamin W
    Pharmazie; 2007 Oct; 62(10):760-6. PubMed ID: 18236781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicochemical compatibility of mixtures of dornase alfa and tobramycin containing nebulizer solutions.
    Krämer I; Schwabe A; Lichtinghagen R; Kamin W
    Pediatr Pulmonol; 2009 Feb; 44(2):134-41. PubMed ID: 19061233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicochemical compatibility of fluticasone-17- propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions.
    Kamin W; Schwabe A; Krämer I
    Int J Chron Obstruct Pulmon Dis; 2007; 2(4):599-607. PubMed ID: 18268934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicochemical compatibility and stability of nebulizable drug admixtures containing Dornase alfa and tobramycin.
    Klemmer A; Krämer I; Kamin W
    Pulm Pharmacol Ther; 2014 Jun; 28(1):53-59. PubMed ID: 24035821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers.
    Kamin W; Schwabe A; Krämer I
    J Cyst Fibros; 2006 Dec; 5(4):205-13. PubMed ID: 16678502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions.
    Akapo S; Gupta J; Martinez E; McCrea C; Ye L; Roach M
    Ann Pharmacother; 2008 Oct; 42(10):1416-24. PubMed ID: 18780805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical and physical compatibility of levalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium, or acetylcysteine sodium.
    Bonasia PJ; McVicar WK; Bill W; Ong S
    Respir Care; 2008 Dec; 53(12):1716-22. PubMed ID: 19025708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical compatibility of nebulizable drug admixtures containing colistimethate and tobramycin.
    Wollstadt A; Krämer I; Kamin W
    Pharmazie; 2013 Sep; 68(9):744-8. PubMed ID: 24147342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compatibility of budesonide inhalation suspension with four nebulizing solutions.
    McKenzie JE; Cruz-Rivera M
    Ann Pharmacother; 2004 Jun; 38(6):967-72. PubMed ID: 15084687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical compatibility of nebulizable drug admixtures containing budesonide and colistimethate or hypertonic saline.
    Klemmer A; Krämer I; Kamin W
    Int J Pharm Compd; 2013; 17(3):254-61. PubMed ID: 24046941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osmolality and pH of anti-asthmatic drug solutions.
    Desager KN; Van Bever HP; Stevens WJ
    Agents Actions; 1990 Nov; 31(3-4):225-8. PubMed ID: 2150739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
    Corrigan DO; Corrigan OI; Healy AM
    Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Osmolarity of solutions used in nebulization].
    Portel L; Tunon de Lara JM; Vernejoux JM; Weiss I; Taytard A
    Rev Mal Respir; 1998 Apr; 15(2):191-5. PubMed ID: 9608990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a stability-indicating high-performance liquid chromatography method for the simultaneous determination of albuterol, budesonide, and ipratropium bromide in compounded nebulizer solutions.
    Blewett AJ; Varma D; Gilles T; Butcher R; Jacob J; Amazan J; Jansen SA
    J AOAC Int; 2011; 94(1):110-7. PubMed ID: 21391487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhalation solutions--which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers--update 2013.
    Kamin W; Erdnüss F; Krämer I
    J Cyst Fibros; 2014 May; 13(3):243-50. PubMed ID: 24172851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a stability indicating RP-HPLC method for the simultaneous determination of related substances of albuterol sulfate and ipratropium bromide in nasal solution.
    Kasawar GB; Farooqui M
    J Pharm Biomed Anal; 2010 May; 52(1):19-29. PubMed ID: 20045275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compatibility of nebulizer solution admixtures.
    Joseph JC
    Ann Pharmacother; 1997 Apr; 31(4):487-9. PubMed ID: 9101012
    [No Abstract]   [Full Text] [Related]  

  • 18. Preservatives in nebulizer solutions: risks without benefit.
    Beasley R; Fishwick D; Miles JF; Hendeles L
    Pharmacotherapy; 1998; 18(1):130-9. PubMed ID: 9469687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compatibility and osmolality of inhaled N-acetylcysteine nebulizing solution with fenoterol and ipratropium.
    Lee TY; Chen CM; Lee CN; Chiang YC; Chen HY
    Am J Health Syst Pharm; 2005 Apr; 62(8):828-33. PubMed ID: 15821276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A technical feasibility study of dornase alfa delivery with eFlow® vibrating membrane nebulizers: aerosol characteristics and physicochemical stability.
    Scherer T; Geller DE; Owyang L; Tservistas M; Keller M; Boden N; Kesser KC; Shire SJ
    J Pharm Sci; 2011 Jan; 100(1):98-109. PubMed ID: 20533437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.